Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference

GlobeNewswire February 25, 2021

Algernon Turns to Dalton Pharma to Help with Stroke Program

Stockhouse Editorial February 19, 2021

Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program

GlobeNewswire February 19, 2021

Algernon Pharmaceuticals (CSE:AGN) releases update on COVID-19 Phase 2b data

Brieanna McCutcheon  February 17, 2021

Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data

GlobeNewswire February 17, 2021

BTV News Alert Video: Algernon Pharmaceuticals Inc. - Trial Complete for COVID-19 Treatment

Newsfile February 11, 2021

Algernon Pharmaceuticals (CSE:AGN) considers adding lung scarring as an endpoint for its Phase 2b/3 COVID-19 study protocol

John Ballem  February 10, 2021

Lung Scarring Could be Another Endpoint for Algernon’s COVID-19 Study

Stockhouse Editorial February 10, 2021

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

GlobeNewswire February 10, 2021

Algernon Pharmaceuticals (CSE:AGN) signs agreement with Charles River Laboratories

Brieanna McCutcheon  February 8, 2021

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

GlobeNewswire February 8, 2021

Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

GlobeNewswire February 3, 2021

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule"

GlobeNewswire February 1, 2021

Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants

GlobeNewswire January 22, 2021

Algernon Approved to Conduct Phase 3 Ifenprodil Study for COVID-19

Stockhouse Editorial January 20, 2021

Algernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated Warrants

GlobeNewswire January 19, 2021

Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19

GlobeNewswire January 19, 2021

Algernon Pharmaceuticals (CSE:AGN) highlights research review identifying potential COVID-19 treatment

Research January 11, 2021

New Research Suggests Ifenprodil as a Potential COVID-19 Treatment

Stockhouse Editorial January 11, 2021

Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment

GlobeNewswire January 11, 2021